ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 2298

Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis

Raul Castellanos-Moreira1, Sebastian Rodriguez-Garcia 2, Virginia Ruiz-Esquide 3, Fernanda Hernández-González 4, Marcelo Sánchez 5, José Ramírez 6, Mariana Benegas 5, Carmen Lucena-Pozo 4, Carlos Agustí 4, Marc Boada 7, Odette Viñas 8, Estíbaliz Ruiz 8, Sergio Prieto-González 9, Jose Gomez-Puerta 1, Jacobo Sellares 4, Juan Cañete 1, Isabel Haro 10 and Raimon Sanmarti 1, 1Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 2Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, 3Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 4Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, 5Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, 6Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, 7Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, 8Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, 9Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, 10Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: autoantibodies, interstitial lung disease, pathogenesis, rheumatoid arthritis, tobacco use and rheumatoid arthritis (RA)

Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated peptides/proteins (anti-CarP) is a new family of RA autoantibodies associated with poor outcomes including an increased mortality due to respiratory disease (1).  We aimed to analyze the prevalence of distinct anti-CarP fine specificities in an established RA cohort and determined whether anti-CarP are associated with ILD.

Methods: Cross sectional study. Patients with RA according to ACR/EULAR 2010 criteria with a disease duration of ≤ 10 years, and those with an associated ILD independently of the disease duration were included. ILD was diagnosed with a high-resolution CT according the American Thoracic Society/European Respiratory Society 2013 criteria, diagnosis confirmed by a multi-disciplinary committee. Demographic, clinical and radiological features were analyzed. Auto-antibody status (RF and ACPA)  were also assessed. Three anti-CarP IgG autoantibodies were determined (anti-CarP fetal calf serum (FCS), anti-CarP fibrinogen (anti-Fib) and anti-CarP fibrine/filagrine homocitrulinated peptide (anti-CFFHP)) by home-made ELISA tests using as antigens either carbamylated proteins or a synthetic chimeric fibrin-filaggrin homocitrullinated peptide. Cut-off values were determined using ROC curves, with a specificity of 96% compared with a healthy population.

Results: 179 patients were included, 21% had an ILD. The mean age at ILD diagnosis was 64.2 (±9.7) years, the mean time from RA diagnosis until ILD diagnosis was 9.3 (IQR: 11.4) years. A significantly greater tobacco exposure (30.7 ±11.1 vs 21.8 ±12) and higher frequency of erosive disease (70% vs 44%) and disability (HAQ-DI >1: 27% vs 12%) was observed in patients with ILD. Total cohort demographic, clinical and radiological features are presented in Table 1.

Anti-CarPs prevalence in the total cohort was 49%, 56%, and 29% for anti-FCS, anti-Fib and anti-CFFHP peptide respectively. Positive Anti-FCS anti-Fib and anti-CFFHP peptide were found in 22%, 29% and 8% of ACPA negative patients respectively.

 All anti-CarP fine specificities were significantly more prevalent in patients with ILD (anti-FCS 70% vs 43%; anti-Fib 73% vs 51%; anti-CFFHP 49% vs 23%), and significantly higher titers of Anti-FCS and anti-CFFCHP were observed in these patients.

A logistic regression model adjusted for age, disease duration, sex, smoking, erosive disease, RF and ACPA demonstrated that Anti-FCS (OR: 3.49; CI 95%: 1.16-10.50) and anti-CFFHP (OR: 4.82; CI 95%: 1.56-14.9) were independently associated with ILD.

Conclusion: In our cohort, the presence of anti-CarP ranges between 29-56% according to the antigenic specificity used. These autoantibodies were associated with ILD. Anti-CarP could be considered a more specific biomarker of ILD in patients with RA rather than ACPA.

Reference

1. Vidal-Bralo L. Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLOS ONE. 2017;12(7):e0180144.


table 1


Disclosure: R. Castellanos-Moreira, None; S. Rodriguez-Garcia, None; V. Ruiz-Esquide, None; F. Hernández-González, None; M. Sánchez, None; J. Ramírez, None; M. Benegas, None; C. Lucena-Pozo, None; C. Agustí, None; M. Boada, None; O. Viñas, None; E. Ruiz, None; S. Prieto-González, None; J. Gomez-Puerta, None; J. Sellares, None; J. Cañete, Eli Lilly and Company, 5, Janssen, 5, 8, Novartis, 5, 8, Mylan, 5, Pfizer, 5, UCB, 5; I. Haro, None; R. Sanmarti, None.

To cite this abstract in AMA style:

Castellanos-Moreira R, Rodriguez-Garcia S, Ruiz-Esquide V, Hernández-González F, Sánchez M, Ramírez J, Benegas M, Lucena-Pozo C, Agustí C, Boada M, Viñas O, Ruiz E, Prieto-González S, Gomez-Puerta J, Sellares J, Cañete J, Haro I, Sanmarti R. Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/interstitial-lung-disease-is-associated-with-distinct-fine-specificities-of-anti-carbamylated-peptide-protein-antibodies-in-rheumatoid-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-lung-disease-is-associated-with-distinct-fine-specificities-of-anti-carbamylated-peptide-protein-antibodies-in-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology